Kidney Transplant Market

Kidney Transplant Market Analysis – Size, Share, and Forecast 2025 to 2035

The Kidney transplant industry is projected to be valued at USD 6.13 billion in 2025. As per FMI's analysis, the kidney transplant industry will grow at a CAGR of 4.2% and reach USD 8.08 billion by 2035. The worldwide kidney transplant industry is anticipated to see consistent growth on account of advances in transplant technology, a rising incidence of CKD, and growing awareness of organ donation.

The growth of the kidney transplant industry was supported by the rising organ donation rates, advancements in transplant techniques, and improved post-transplant care in 2024. A major advancement was the development of machine perfusion technologies that kept donor kidneys alive longer and helped reduce organ wastage and improve transplant outcomes.

The increasing need for kidney transplantation is driven by the increasing incidence of diabetes and hypertension, which are major causes of CKD. Moreover, advancements in technology in the form of better immunosuppressive therapy, organ preservation methods, and xenotransplantation advancements are increasing transplant success rates. Nevertheless, the sector is hindered by issues like organ scarcity, the expense of transplants, and complications following transplantation.

Intraocular Lymphoma Treatment Market Analysis – Size, Share, and Forecast 2025 to 2035

The kidney transplant industry is on a consistent growth path, fueled by increasing chronic kidney disease (CKD) cases, organ preservation and transplant technology advancements, and heightened organ donation awareness.

Biotechnology companies, medical device manufacturers, and transplant facilities will gain from developments such as machine perfusion, artificial intelligence-based organ matching, and xenotransplantation, while patients in low-income areas will be disadvantaged by exorbitant costs and organ shortages. As governments and healthcare systems continue to invest in enhancing access to transplants, the industry will keep growing, with the Asia-Pacific region becoming a major growth area.

Top 3 Strategic Imperatives for Stakeholders

Budget for Advanced Organ Preservation and Transplant Technologies

Treatment modalities like machine perfusion technology, Artificial Intelligence based organ matching, and 3D bioprinting can help boost organ transplant success rate and reduce wastage. Collaborating with biotech companies and healthcare institutions can speed up research & segment expansion.

Drive Accessibility& Affordability in Emerging Sectors

To not only help improve transplant affordability, especially in the Asia-Pacific and Latin America regions, where CKD is reaching epidemic levels, companies should align with healthcare policies and healthcare reimbursement models. Cost reduction and sector coverage can best be achieved through public-private partnerships and local manufacturing.

Enhance Supply Chain & Strategic Partnerships

To combat organ shortages and speed up distribution, stakeholders need to work with organ donation networks, create blockchain-based donor registries and explore xenotransplantation advances. Mergers, acquisitions, and cross-industrypartnerships with AI developers and biotech firms can lead to competitive advantages in the fast-evolving transplant landscape.

Top 3 Risks Stakeholders Should Monitor

1-Year Executive Watchlist

For the Boardroom

As the kidney transplant industry continues to change, the next step in the discussion is to innovate quickly, become more accessible, and form key partnerships. Unique strategic projects, such as machine perfusion, AI-organ matching, and xenotransplantation, will set segment leaders apart while positively impacting patient outcomes. Simultaneously, globalization through local manufacturing and public-private partnerships in emerging sectors enables new revenues. Overcoming regulatory hurdles and affordability barriers will be key to long-term success.

Future Market Insights (FMI) Survey Results on the Kidney Transplant Landscape

Key Priorities of Stakeholders

• Expanding Organ Availability: 79% of stakeholders globally identified increasing organ supply through better donor programs and alternative sources (e.g., xenotransplantation, bioengineered organs) as a “critical” priority.
• Reducing Transplant Costs: 71% emphasized the need for cost-efficient solutions, particularly for immunosuppressive drugs and post-transplant care.

Regional Variance:

• USA: 64% highlighted the importance of AI-based organ matching, compared to 38% in Japan.
• Western Europe: 85% emphasized sustainability in organ transport (e.g., green cooling technologies), compared to 50% in the USA.
• Japan/South Korea: 59% focused on miniaturized organ perfusion devices due to space and cost constraints, compared to 33% in the USA.

Embracing Sophisticated Technologies

High Variance:

• USA: 57% of transplant centers implemented AI-driven organ matching, reducing waitlist times.
• Western Europe: 52% adopted machine perfusion for improved organ viability, with Germany (68%) leading due to strict transplant regulations.
• Japan: Only 26% used advanced perfusion devices, citing cost concerns.
• South Korea: 40% invested in 3D bioprinting research for potential future kidney regeneration.

Convergent and Divergent Perspectives on ROI:

• 69% of USA stakeholders saw AI-based transplant solutions as "worth the investment," while Japan (41%) still relied on traditional matching techniques.

Organ Source Preferences

Consensus:

• Deceased Donor Transplants: Chosen by 72% of participants, with a focus on improving organ preservation.

Variance:

• Western Europe: 49% supported xenotransplantation (e.g., genetically modified pig kidneys), compared to 22% in Japan.
• Japan/South Korea: 37% supported lab-grown kidney research due to cultural hesitancy toward organ donation.
• USA: 65% favored living-donor transplants, with increasing interest in paired kidney exchange programs.

Cost Sensitivity

Shared Challenges:

• 87% cited rising medical costs (immunosuppressive drugs up 20%, surgical costs up 15%) as a major issue.

Regional Differences:

• USA/Western Europe: 58% would pay a 10-15% premium for enhanced transplant success rates via advanced preservation techniques.
• Japan/South Korea: 76% preferred lower-cost transplant procedures (< USD 100,000 total cost) over premium technologies.
• South Korea: 48% favored government-subsidized transplant programs, compared to 19% in the USA.

Pain Points in the Value Chain

Hospitals & Transplant Centers:

• USA: 54% reported surgeon shortages, impacting transplant wait times.
• Western Europe: 46% cited complex EU regulatory compliance as a barrier to innovation.
• Japan: 59% struggled with slow patient adoption of new transplant techniques.

Medical Device Manufacturers:

• USA: 69% faced supply chain disruptions for critical transplant equipment.
• Western Europe: 51% cited competition from lower-cost Asian medical device manufacturers.
• Japan/South Korea: 62% highlighted high R&D costs for new transplant solutions.

Patients & Donors:

• USA: 43% cited long wait times as their biggest challenge.
• Western Europe: 38% struggled with high out-of-pocket expenses.
• Japan: 57% mentioned a lack of transplant awareness and education as a key issue.

Future Investment Priorities

Alignment:

• 76% of medical device manufacturers plan to invest in AI-powered transplant technologies.

Divergence:

• USA: 60% focused on scaling AI-based transplant matching and logistics optimization.
• Western Europe: 56% invested in green technology for organ transport and preservation.
• Japan/South Korea: 48% prioritized miniaturized and cost-efficient preservation devices.

Regulatory Impact

USA:

• 67% said evolving state-level transplant laws (e.g., California’s expanded donor incentives) were “highly influential” in industry growth.

Western Europe:

• 79% viewed the EU’s Organ Donation and Transplantation Directive 2024 as a driver for stricter regulations but better funding.

Japan/South Korea:

• Only 35% saw regulatory shifts as impactful, citing slower enforcement and lower public participation in organ donation programs.

Conclusion: Variance vs. Consensus

High Consensus:

• Increasing organ availability, reducing transplant costs, and improving transplant success rates remain global priorities.

Key Variances:

• USA: Leading in automation and AI-based transplant solutions
• Western Europe: Sustainability and regulation-driven innovation vs. Asia: Pragmatic, cost-effective solutions.

Strategic Insight:

• A "one-size-fits-all" approach will not succeed. Region-specific strategies (e.g., AI adoption in the USA, green technology in Europe, and cost-efficient solutions in Asia) will be key to breaking into global sectors.

Government Regulations Impact on the Kidney Transplant Landscape

Country-wise Analysis

United States

The USA will grow at a rate of 3.2% CAGR during 2025 to 2035, is expected to lead key growth segments, due to favorable government support, increasing technological advancements and high organ transplant rates. There is a well-regulated organ allocation process through UNOS (the United Network for Organ Sharing) and the OPTN (Organ Procurement and Transplantation Network) which makes the organ allocation system efficient.

With AI-driven algorithms for organ matching, machine perfusion technologies and xenotransplantation research, the USA is at the forefront. The National Organ Transplant Act (NOTA) prohibits the sale of human organs, but facilitates paired kidney exchanges to increase transplantation accessibility. The expansion of private insurance coverage and state level incentives will further drive segment growth.

United Kingdom

The UK kidney transplant segment is poised to increase at a CAGR of 2.9% from 2025 to 2035, bolstered by NHS blood and transplant (NHSBT) initiatives and the controversial, organ procurement process in place of Max and Keira's Law. Such a policy has expanded the pool of available deceased donor organs, and decreased wait times.

The UK has been at the forefront of adopting minimally invasive transplant techniques and hypothermic machine perfusion (HMP) technology behind enhanced transplant success rates. The MHRA is independent but is obliged to register its recommendations on transplant drugs and medical devices under EU MDR. High costs required for transplant, an underfunded NHS budget, and ongoing regulatory changes as a result of Brexit, which has put pressure on imports of medical devices.

France

France’s kidney transplant sector will expand at a compound annual growth rate (CAGR) of 2.7% between 2025 and 2035; it has seen an increase in organ availability as a result of the country's opt-out donation law. Recent advances in organ preservation technology and hypothermic machine perfusion (HMP) were accompanied in France by leadership in their implementation, to the extent that transplant centers use such technologies as a standard.

Public-private collaborations supported by the government are driving innovation in bioprinting and artificial organs. France also grapples with regional inequalities in transplant access, where rural hospitals lack the high-tech infrastructure to perform kidney transplants. The industry will be fueled by AI-enabled transplant matching and the evolution of minimally invasive surgery in the future.

Germany

The German kidney transplant segment is expected to grow at a compound annual growth rate (CAGR) of 2.4% in the 2025 to 2035 period, attributable to robust public healthcare financing and advanced transplant research. Germany still has one of the lowest donor rates in western Europe, which in turn limits organ transplants.

Germany is pioneer in robotic kidney transplant surgery and AI-based donor-recipient matching, essential to profile the best donor-recipient according to compatibility, thus reducing risks and complications and improving outcomes. Transplant analytics could be among the first fields affected, but EU legislation on medical devices (EU MDR) and data protection (GDPR) are also hindering the adoption of AI.Cost remains a significant barrier, as the high average cost of a kidney transplant has led to increased demand for cross-border transplants in the EU.

Italy

Italy’s kidney transplant segment is expected to sustain a CAGR of 2.6% from 2025 to 2035, buoyed by a well-established national organ donation network. Transplant legislation is supervised by the Centro Nazionale Trapianti (CNT), which is responsible for equitable organ distribution. Italy boasts one of the highest rates of living-donor kidney transplant in Europe, and a significant use of robotic-assisted transplant surgeries.

Italy faces challenges such as unequal healthcare access across regions and the slow adoption of AI-based organ allocation systems. Funding for regenerative medicine and organ preservation technology is also growing, highlighted by large investments in xenotransplantation and stem-cell therapies. Economic instability and high medical device import costs may constrain short-term growth.

South Korea

South Korea kidney transplant landscape is poised to grow at a CAGR of 2.8% from 2025 to 2035, owing to the rapid adoption of medical technologies, a strong universal healthcare system and government-supported insurance coverage for transplant patients. It has one of the highest per capita healthcare costs in Asia, and the government strongly supports organ transplantation.

The Korean network for organ sharing (KONOS) is responsible for allocation and transplant policies in South Korea, in accordance with principles of fairness and ethics. Robot-assisted kidney transplantation (RAKT) is gaining popularity led by hospitals like Seoul National University Hospital and Asan Medical Center augmenting real-time AI-powered donor-recipient matching algorithm to increase the success rates of transplant operations.

Japan

Japan's kidney transplant segment is forecast to grow at a CAGR of 2.3% between the years 2025 to 2035, lower than the worldwide average owing to cultural and regulatory challenges. It has one of the lowest deceased organ donation rates among developed nations, partly because of cultural beliefs that relate to death and organ removal. The law on organ transplants (OTL), which requires consent from family members to perform organ retrieval, adds further obstacles.

As a result, Japan is deeply dependent on living donors, who make up almost 85 percent of all kidney transplants. This has resulted in long waiting lists to receive a deceased donor transplant, often over 10 years at major hospitals. Japan is now heavily investing in artificial kidney development, stem-cell therapies and 3D bioprinting to address the organ shortage. Among those leading this research into regenerative medicine for kidney failure are JCR Pharmaceuticals and Kyoto university’s iPS cell research institute.

China

The China kidney transplant industry is expected to grow at a CAGR of about 3.1% between 2025 and 2035 mainly due to the health care reform supported by the central government, an increasing voluntary donor registry, and substantial investments in transplant research. China performs one of the largest volumes of kidney transplants in the world, with more than sixteen thousand transplants conducted.

Transplant-related medical devices and pharmaceuticals are overseen and regulated for compliance with Good Manufacturing Practices (GMP) by the National Medical Products Administration (NMPA). The Chinese National Organ Donation and Transplantation Committee (CNODTC) played a key role in moving from unethical sourcing practices to an incentivized, voluntary system that aims to minimize harm and increase voluntary organ donations ethically.

Australia & New Zealand

The kidney transplant sector of New Zealand and Australia are projected to grow with a CAGR of 2.7% during the period from 2025 to 2035, bolstered by high organ donation rates, a universal healthcare system, and substantial government funding for transplant programs. With donor awareness campaigns launched by the Australian Organ and Tissue Authority (OTA), Australia has one of the highest deceased donor rates in the Asia-Pacific region.

Australia and New Zealand were among the early adopters of AI-based transplant matching and robotic-assisted kidney transplant surgeries, leading to better efficiency of transplantations. It includes research institutes like Monash University and the University of Sydney, which are also pursuing stem-cell-based kidney regeneration and organ bio engineering. Other issues include regional differences in transplant availability and access, especially in rural and indigenous areas with limited hospital infrastructure.

India

India is anticipated to be the fastest-growing kidney transplant segment during the period 2025 to 2035 with a CAGR of 3.3% driven by the increasing cases of chronic kidney disease (CKD), growing private healthcare sector and medical tourism. While the National Organ & Tissue Transplant Organisation (NOTTO) is responsible for organ allocation, the country faces considerable common challenges including an illegal organ segment, insufficient deceased donors and substantial out-of-pocket transplant costs.

Leading hospitals, like the Apollo Hospitals Group and AIIMS, have begun incorporating robotic-assisted kidney transplant procedures into their offerings as well as AI-powered transplant logistics to streamline processes. India serves as a global destination for organ transplants to patients from the Middle East, Africa, and Southeast Asia because of much cheaper transplant procedures.

Segment-wise Analysis

By Transplant

The global transplant segment and grow at a CAGR of 4.2% between 2025 and 2035. Deceased-donor kidney transplants had the largest market share among transplant types, fueled by increasing market awareness regarding organ donation along with technological developments in organ preservation.

Living-donor kidney transplants are the most rapidly expanding segment because of higher rates of success, shorter wait times, and improved minimally invasive donor nephrectomy surgeries. In many countries, there are public awareness campaigns and government incentives that are helping to promote living donation as the best option for donation in terms of utilitarianism.

By Age Group

The industry is expected to expand at a CAGR of 3.1% during this period, with varying growth rates across different segments. A breakdown by age group reveals that adult kidney transplants account for the vast majority of the segment, with approximately 92% of the total share in 2025.

This is mainly due to the increasing rates of chronic diseases, such as diabetes and hypertension in adults, which increases the demand for transplants. Even though the pediatric segment is smaller, it is also experiencing steady growth as surgical techniques and post-operative care improve, leading to higher survival rates among young patients.

By End User

The kidney transplant industry is projected to grow at a CAGR of 3.1% from 2025 to 2035. By end user, hospitals have steadfastly been the leading segment globally with over half of all kidney transplants taking place in this setting. They are dominant because of their infrastructure, access to complete databases of patients, and higher-risk procedures.

On the other hand, transplant centers are turning into specialized institutes providing focused care, thus boosting the sector. Awareness of the importance of cross-organ collaboration is relatively young, but academic and research institutes are a major driver of innovation in these individual areas (transplant techniques, immunosuppressive drugs, and regenerative medicine), although they usually do not directly perform procedures.

Competitive Landscape

Pricing strategies, technological innovations, strategic partnerships, and geographical expansion are some of the key areas where the leading companies in the kidney transplant sector are focusing their efforts to gain an edge over their competitors. As healthcare costs climb, businesses are prioritizing cost-efficient transplant solutions, such as minimally invasive surgical methods and new organ preservation technologies, to make it more accessible.

Companies are partnering with organ procurement organizations (OPOs), transplant centers, and biotech companies to increase organ availability. With the increasing CKD cases and investment in healthcare, expansion into emerging sectors, especially in India, China, and South-East Asia, is a major focus. Firms also work with government agencies and regulators to create policies that promote organ donation and transplantation.

Market Share Analysis

• The global kidney transplant industry is highly competitive, with key players dominating significant shares.
• In 2025, Novartis AG is expected to lead with around 25-30% industry share, driven by its immunosuppressive drugs like Myfortic and Simulect.
• Sanofi and Pfizer follow closely, each holding 15 to 20%, due to their strong portfolios in transplant-related medications.
• Emerging biotech firms, such as Veloxis Pharmaceuticals (now part of CSL Behring), account for 10-15%, focusing on innovative immunosuppressive therapies.
• The remaining 20-25% is fragmented among regional players, hospitals, and research institutions specializing in transplant technologies.

Key Developments

• In March 2024, Novartis received FDA approval for a new immunosuppressive drug designed to reduce organ rejection with fewer side effects, strengthening its segment dominance.
• CSL Behring acquired a biotech startup specializing in organ preservation solutions in early 2025, expanding its portfolio in transplant innovation.
• Sanofi partnered with a leading AI-driven diagnostics firm in late 2024 to improve post-transplant monitoring using predictive analytics.
• The FDA fast-tracked a breakthrough bioengineered kidney graft in January 2025, with clinical trials led by United Therapeutics, potentially revolutionizing transplant availability.
• Pfizer faced a temporary setback when its key transplant drug saw supply chain delays in Q4 2024, but production resumed by early 2025.

Key Players

• AbbVie Inc.
• Astellas Pharma Inc.
• F. Hoffmann-La Roche Ltd.
• Sanofi S.A.
• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Medtronic plc
• TransMedics Group, Inc.
• Veloxis Pharmaceuticals, Inc.
• BioMérieux SA
• OrganOx Limited
• XVIVO Perfusion AB
• Terumo Corporation

Key Segments

By Transplant:

Deceased-Donor Kidney Transplant, Living-Donor Kidney Transplant (Direct Donation Kidney Transplant, Non-directed Donation Kidney Transplant, and Paired exchange Kidney Transplant)

By Age Group:

Adult and Pediatric

By End User:

Transplant Centres, Hospitals, and Academic and Research Institutes

By Region:

North America, Latin America, Europe, South Asia, East Asia, Oceania, and The Middle East and Africa (MEA)